[Levamisol in the treatment of recurrent urinary tract infections]. 1979

A M Lubetkin, and R F Remedi, and M Granero, and O Brarda

Levamisole, a widely used antihelminthic drug, possesses immunotropic properties. It has been proved that children with recurrent infections of the respiratory tract who were given the drug, were capable of preventing the repetition of the infections. Twenty-seven (27) children with recurrent urinary tract infections without structural malformations were studied and in all of them, a diminished cellular immunity was detected (blastic transformation of lymphocytes, rosettes of T lymphocytes and the skin tests). The drug was administered in doses of 2.5 mg/k/day, twice a week, for eight months. During the period of study, in 21 children repetition of the infections were not detected and in 13, a significant improvement of the cellular immunity was achieved. In some children it was possible to prove a rise of the IgA secretary in the urine.

UI MeSH Term Description Entries
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D007978 Levamisole An antihelminthic drug that has been tried experimentally in rheumatic disorders where it apparently restores the immune response by increasing macrophage chemotaxis and T-lymphocyte function. Paradoxically, this immune enhancement appears to be beneficial in rheumatoid arthritis where dermatitis, leukopenia, and thrombocytopenia, and nausea and vomiting have been reported as side effects. (From Smith and Reynard, Textbook of Pharmacology, 1991, p435-6) L-Tetramisole,Levotetramisole,Decaris,Dekaris,Levamisole Hydrochloride,Solaskil,Hydrochloride, Levamisole
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008297 Male Males
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females

Related Publications

A M Lubetkin, and R F Remedi, and M Granero, and O Brarda
July 1990, Casopis lekaru ceskych,
A M Lubetkin, and R F Remedi, and M Granero, and O Brarda
December 2005, Best practice & research. Clinical obstetrics & gynaecology,
A M Lubetkin, and R F Remedi, and M Granero, and O Brarda
November 1988, Giornale di clinica medica,
A M Lubetkin, and R F Remedi, and M Granero, and O Brarda
December 1988, The Western journal of medicine,
A M Lubetkin, and R F Remedi, and M Granero, and O Brarda
December 2005, Enfermedades infecciosas y microbiologia clinica,
A M Lubetkin, and R F Remedi, and M Granero, and O Brarda
April 2016, American family physician,
A M Lubetkin, and R F Remedi, and M Granero, and O Brarda
December 2005, Der Internist,
A M Lubetkin, and R F Remedi, and M Granero, and O Brarda
September 2021, Obstetrics and gynecology clinics of North America,
A M Lubetkin, and R F Remedi, and M Granero, and O Brarda
January 1963, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
A M Lubetkin, and R F Remedi, and M Granero, and O Brarda
July 1993, Canadian family physician Medecin de famille canadien,
Copied contents to your clipboard!